Alcobra Pharmaceuticals
Treatment of Cognitive Disorders
Company Overview
Snapshot
Founded in February 2008, Alcobra Pharmaceuticals operated with 1–10 employees and raised $25 million across one funding round. The company was acquired by Arcturus Therapeutics Inc. in November 2017.
Business overview
Alcobra Pharmaceuticals was a pharmaceutical company focused on developing and commercializing Metadoxine Extended Release (MDX), a proprietary drug designed to treat cognitive disorders. Its core technology, MDX, was developed to address conditions such as attention-deficit/hyperactivity disorder (ADHD) and Fragile X syndrome, operating through a non-stimulant mechanism of action. The company served the healthcare and life sciences sectors, specifically targeting patients with neurological disorders.
Strategic signal
In November 2017, Alcobra Pharmaceuticals completed its merger with Arcturus Therapeutics Inc., marking its exit from the market. This acquisition followed a period where Alcobra's clinical trial for its main ADHD product failed, signaling a strategic shift for the company to integrate its assets into a larger entity.
Log in to access full profile ›Company Intelligence Q&A
- When was Alcobra Pharmaceuticals acquired?
- Alcobra Pharmaceuticals was acquired by Arcturus Therapeutics Inc. in November 2017.
- What was the outcome of Alcobra Pharmaceuticals' clinical trials for its ADHD drug?
- In October 2014, Alcobra Pharmaceuticals experienced a significant drop in stock value following the results of its Phase III clinical trial for its ADHD drug.
- Did Alcobra Pharmaceuticals receive any special designations for its Fragile X drug?
- In September 2015, Alcobra Pharmaceuticals was awarded Fast Track designation for its Fragile X drug.
- What was the total capital raised by Alcobra Pharmaceuticals?
- Alcobra Pharmaceuticals raised a total of $25 million across one funding round.